Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
For investors considering Adtalem Global Education, the story hinges on believing in the ongoing demand for healthcare education and the company's ability to adapt as student financing shifts. The new collaboration with Sallie Mae is a meaningful development, arriving just as federal Grad PLUS loans are being phased out, which could have posed a significant funding risk for Adtalem’s student base. This partnership could offset some of that risk and support the company's 2026 revenue growth guidance, serving as a short-term catalyst if executed smoothly. At the same time, the company’s credit facility expansion gives it extra financial flexibility. While recent earnings and revenue figures are strong, with guidance for further growth, the reliance on successful rollout of alternative loan products adds a new variable to watch that may change the risk profile for shareholders in the near term. On the flip side, share price momentum following the news suggests optimism about managing these shifts, but the real test will be in delivering student funding solutions without disruption to enrollment or margins. Yet, there’s another side to the story, with any alternative financing, transition risks for students and Adtalem remain a key issue to monitor.
Adtalem Global Education's shares have been on the rise but are still potentially undervalued by 37%. Find out what it's worth.Explore 2 other fair value estimates on Adtalem Global Education - why the stock might be worth as much as 58% more than the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com